Información del artículo
Abstract
Resistance to insulin action is a feature that accompanies certain diseases among which chronic inflammatory states like rheumatoid arthritis are included. What is, what its pathogenesis is, how it is measured, and what clinical and therapeutic implications have in rheumatoid arthritis patients is a topic not familiar to rheumatologists that is reviewed in this paper.
Keywords:
Insulin resistance
Rheumatoid arthritis
Resumen
La resistencia a la acción de la insulina es una situación clínica que suele acompañar a las enfermedades inflamatorias crónicas como la artritis reumatoide. Su presencia puede aumentar la morbi-mortalidad de las enfermedades a las que se asocia. En qué consiste, cuál es su etiopatogenia, cómo se mide y qué implicaciones clínicas y terapéuticas tiene en pacientes con artritis reumatoide es un tema que no es familiar para reumatólogos y que abordamos en esta revisión.
Palabras clave:
Resistencia a la insulina
Artritis reumatoide
El Texto completo está disponible en PDF
References
[1.]
A.J. Krentz, G. Clough, C.D. Byrne.
Vascular disease in the metabolic syndrome: do we need to target the microcirculation to treat large vessel disease?.
J Vasc Res, 46 (2009), pp. 515-526
[2.]
Executive Summary of The Third Report of The National Cholesterol Education. Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
[3.]
R. Muniyappa, S. Lee, H. Chen, M.J. Quon.
Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage.
American Journal of Physiology, 294 (2008), pp. E15-E26
[4.]
D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner.
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
Diabetologia, 28 (1985), pp. 412-419
[5.]
L. Roytblat, M. Rachinsky, A. Fisher, L. Greemberg, Y. Shapira, A. Douvdevani, et al.
Raised interleukin-6 levels in obese patients.
Obes Res, 8 (2000), pp. 673-675
[6.]
M. Straczkowski, S. Dzienis-Straczkowska, A. Stepien, I. Kowalska, M. Szelachowska, I. Kinalska.
Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system.
J Clin Endocrinol Metab, 87 (2002), pp. 4602-4606
[7.]
G.S. Hotamisligil, P. Arner, J.F. Caro, R.L. Atkinson, B.M. Spiegelman.
Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.
J Clin Invest, 95 (1995), pp. 2409-2415
[8.]
C.X. Andersson, B. Gustafson, A. Hammarstedt, S. Hedjazifar, U. Smith.
Inflamed adipose tissue, insulin resistance and vascular injury.
Diabetes Metab Res. Rev, 24 (2008), pp. 595-603
[9.]
C. De Luca, J.M. Olefsky.
Inflammation and insulin resistance.
FEBS lett, 582 (2008), pp. 97-105
[10.]
J. Hirosumi, G. Tuncman, L. Chang, C.Z. Gorgun, K.T. Uysal, K. Maeda, et al.
A central role for JNK in obesity and insulin resistance.
Nature, 420 (2002), pp. 333-336
[11.]
H. Sugita, M. Fujimoto, T. Yasukawa, N. Shimizu, M. Sugita, S. Yasuhara, et al.
Inducible nitric-oxide synthase and NO donor induce insulin receptor substrate-1 degradation in skeletal muscle cells.
J Biol Chem, 280 (2005), pp. 14203-14211
[12.]
H.J. Kim, T. Higashimori, S.Y. Park, H. Choi, J. Dong, Y.J. Kim, et al.
Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo.
Diabetes, 53 (2004), pp. 1060-1067
[13.]
S.P. Weisberg, D. Hunter, R. Huber, J. Lemieux, S. Slaymaker, K. Vaddi, et al.
CCR2 modulates inflammatory and metabolic effects of high-fat feeding.
J Clin. Invest, 116 (2006), pp. 115-124
[14.]
P.H. Dessein, B.I. Joffe.
Insulin resistance and impaired beta cell function in rheumatoid arthritis.
Arthritis Rheum, 54 (2006), pp. 2765-2775
[15.]
C.P. Chung, A. Oeser, J.F. Solus, T. Gebretsadik, A. Shintani, I. Avalos, et al.
Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms.
Arthritis Rheum, 58 (2008), pp. 2105-2112
[16.]
G. La Montagna, F. Cacciapuoti, R. Buono, D. Manzella, G.A. Mennillo, A. Arciello, et al.
Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis.
Diab Vasc Dis Res, 4 (2007), pp. 130-135
[17.]
P.H. Dessein, G.R. Norton, A.J. Woodiwiss, B.I. Joffe, A. Solomon.
Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis.
J Rheumatol, 34 (2007), pp. 681-688
[18.]
O.N. Pamuk, E. Unlu, N. Cakir.
Role of insulin resistance in increased frequency of atherosclerosis detected by carotid ultrasonography in rheumatoid arthritis.
J Rheumatol, 33 (2006), pp. 2447-2452
[19.]
P.H. Dessein, B.I. Joffe, A. Stanwix, A.S. Botha, Z. Moomal.
The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis.
J Rheumatol, 29 (2002), pp. 462-466
[20.]
O. Oncul, C. Top, S. Ozkan, S. Cavuslu, M. Danaci.
Serum interleukin 2 levels in patients with rheumatoid arthritis and correlation with insulin sensitivity.
J Int Med Res, 30 (2002), pp. 386-390
[21.]
D. Garcia Diaz Jde, A. Lopez de Guzman, L. Sivera Monzo, E. Cuende Quintana.
Significado de la resistencia a la insulina en la enfermedad vascular asociada a la artritis reumatoide.
Med Clin (Barc), 130 (2008), pp. 197-198
[22.]
P.H. Dessein, B.I. Joffe, A.E. Stanwix.
Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study.
Arthritis Res, 4 (2002), pp. R12
[23.]
E. Martinez-Abundis, C. Reynoso-von Drateln, E. Hernandez-Salazar, M. Gonzalez-Ortiz.
Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus.
Arch Dermatol Res, 299 (2007), pp. 461-465
[24.]
A. Rosenvinge, R. Krogh-Madsen, B. Baslund, B.K. Pedersen.
Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy.
Scand J Rheumatol, 36 (2007), pp. 91-96
[25.]
J. Lo, L.E. Bernstein, B. Canavan, M. Torriani, M.B. Jackson, R.S. Ahima, et al.
Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome.
Am J Physiol Endocrinol Metab, 293 (2007), pp. E102-E109
[26.]
B. Seriolo, C. Ferrone, M. Cutolo.
Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity.
J Rheumatol, 35 (2008), pp. 355-357
[27.]
B. Seriolo, S. Paolino, C. Ferrone, M. Cutolo.
Impact of long-term anti-TNF-alpha treatment on insulin resistance in patients with rheumatoid arthritis.
Clinical and Experimental Rheumatology, 26 (2008), pp. 159-160
[28.]
F.M. Oguz, A. Oguz, M. Uzunlulu.
The effect of infliximab treatment on insulin. resistance in patients with rheumatoid arthritis.
Acta Clin Belg, 62 (2007), pp. 218-222
[29.]
F.C. Huvers, C. Popa, M.G. Netea, F.H. Van den Hoogen, C.J. Tack.
Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases.
Ann Rheum Dis, 66 (2007), pp. 558-559
[30.]
L.S. Tam, B. Tomlinson, T.T. Chu, T.K. Li, E.K. Li.
Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis.
Clin Rheumatol, 26 (2007), pp. 1495-1498
[31.]
M.A. González-Gay, J.M. De Matias, C. González-Juanatey, C. Garcia-Porrua, A. Sánchez-Andrade, J. Martin, et al.
Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis.
Clin Exp. Rheumatol, 24 (2006), pp. 83-86
[32.]
D.N. Kiortsis, A.K. Mavridis, S. Vasakos, S.N. Nikas, A.A. Drosos.
Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis.
Ann Rheum Dis, 64 (2005), pp. 765-766
[33.]
G. Pagano, A. Bruno, P. Cavallo-Perin, L. Cesco, B. Imbimbo.
Glucose intolerance after short-term administration of corticosteroids in healthy subjects.
Prednisone, deflazacort, and betamethasone. Arch Intern Med., 149 (1989), pp. 1098-1101
[34.]
C.P. Chung, A. Oeser, J.F. Solus, I. Avalos, T. Gebretsadik, A. Shintani, et al.
Prevalence. of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis.
Atherosclerosis, 196 (2008), pp. 756-763
[35.]
P.H. Dessein, M. Tobias, M.G. Veller.
Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis.
J Rheumatol, 33 (2006), pp. 2425-2432
Copyright © 2011. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
